(2026). Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer. eLife.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Blocking SHP2 Benefits FGFR2 Inhibitor and Overcomes Its Resistance in FGFR2-amplified Gastric Cancer."
ELife 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Blocking SHP2 Benefits FGFR2 Inhibitor and Overcomes Its Resistance in FGFR2-amplified Gastric Cancer."
ELife, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.